Home

Articles

Get our Free
Newsletter!

Vote in our Opinion Polls

Tell a Friend!

Contact us

Voting recommendations

Company: CNOOC Limited (CNOOC)
Stock code: 0883
Meeting type: Annual
Date of meeting: 28-Apr-04
Time of meeting: 10:30
Advice date:  19-Apr-04
CCASS voting cut-off   23-Apr-04. VOTE NOW

Notice of Meeting:

Click here
Voting method: Webb-site.com will require a poll, all proxies will be counted
How to vote: See our voting guide

Note to journalists:
We have up to 4 proxy seats available inside this AGM. Please contact us if you want one.

Item Description Vote
1 Adopt the accounts FOR
2 Declare a final dividend and special dividend FOR
3.1 Re-elect Shouwei Zhou as Executive Director FOR
3.2 Re-elect Kenneth S Courtis as INED AGAINST
3.3 Re-elect Erwin Schurtenberger as INED AGAINST
3.4 Elect Evert Henkes as INED FOR
4 Re-appoint Ernst & Young FOR
5 Mandate the directors to repurchase shares FOR
6 Mandate the directors to issue additional shares AGAINST
7 Mandate the directors to issue repurchased shares AGAINST
9 Amend the articles of association FOR

Reasons AGAINST

Items 3.2 and 3.3

We are advising you to vote AGAINST the re-election of 2 independent non-executive directors of CNOOC, Dr Kenneth S Courtis and Dr Erwin Schurtenberger, because we think they have done a poor job in advising minority shareholders to approve loans made by CNOOC to CNOOC Finance Corp Ltd, a subsidiary of CNOOC's parent, China National Offshore Oil Corporation. It is a golden rule of good governance that listed companies should not lend money to their parents. CNOOC is seeking approval for this in a separate EGM taking place on the same day as the AGM, and we advise you to vote against. Please see our separate voting advice on that meeting.

Of course, CNOOC's parent is allowed under Hong Kong's whacky Listing Rules to vote on the re-elections of its so-called independent directors, thereby ensuring the outcome, but your protest votes will count.

Mr Evert Henkes, a former Shell executive who was appointed by the board during the year and now stands for election, escapes our criticism only because he did not participate in the independent board committee which recommended the loans, but this begs the question of why he did not participate in that committee.

Items 6 and 7

Webb-site.com urges all investors to vote against the general issue mandate for all listed companies, for the reasons explained in Project Vampire, unless they comply with the recommendations set out in that article. The non-pre-emptive issue mandate allows management to choose the shareowners by allotment of shares. This corrupts the governance mechanism. Shareowners should govern management, not the other way around. If a company wishes to raise cash by issuing shares, then it should do so by rights issue.

If your company offers new shares to other investors at a discount, but not to you, then your company is transferring value from you to the new investors. Their gain is your loss. That's why we believe an issue for cash should be done by rights issue, failing which it should be limited to 5% of existing issued shares and a maximum discount of 5%.

Copyright Webb-site.com, 2004


Sign up for our free newsletter

Recommend Webb-site.com to a friend

Important notice: All material on this site, except where otherwise accredited, is copyright to Webb-site.com. Media and researchers are welcome to quote from articles on this site, provided that such quotation is attributed to Webb-site.com. The information in this site should not be relied upon by any person in making any investment decision. No responsibility or liability is accepted by Webb-site.com or any person related to it for any loss arising from or in reliance upon the whole or any part of the contents of this site. Persons who are in any doubt about an investment or potential investment should take professional investment advice. From time to time parties associated with Webb-site.com may own long or short positions in securities issued by or related to companies or governments on which we comment.

Back to top